HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
cyclo(leucylglycine)
RN given refers to cpd without isomeric designation
Also Known As:
cyclo(Gly-Leu); cyclo(Leu-Gly); cyclo(glycylleucyl); cyclo(leucylglycine), (S)-isomer; 3-(2-methylpropyl)-2,5-piperazinedione
Networked:
10
relevant articles (
2
outcomes,
3
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Nerve Tissue Proteins: 2
Neuropeptides: 6772
cyclo(leucylglycine): 10
Peptides: 82426
Neuropeptides: 6772
cyclo(leucylglycine): 10
Cyclic Peptides: 530
cyclo(leucylglycine): 10
Polycyclic Compounds: 6
Macrocyclic Compounds: 15
Cyclic Peptides: 530
cyclo(leucylglycine): 10
Related Diseases
1.
Amnesia (Dissociative Amnesia)
05/01/1979 - "
The time course of distribution of labeled cyclo(Leu-Gly) in subcellular fractions of mouse brain was also examined, and the concentration of peptide in the synaptosomal fraction was significantly correlated with the degree of protection against puromycin-induced amnesia of a maze-learning test.
"
05/01/1979 - "
Distribution, survival and biological effects in mice of a behaviorally active, enzymatically stable peptide: pharmacokinetics of cyclo(Leu-Gly) and puromycin-induced amnesia.
"
01/01/1978 - "
The peptide Z-Pro-Leu-Gly-NH2 attenuated puromycin-induced amnesia in mice when administered 5 days prior to training, while arginine vasopressin, lysine vasopressin and cyclo(Leu-Gly), were effective when given 24 hr before training.
"
2.
Tardive Dyskinesia
01/01/1983 - "
Cyclo(Leu-Gly): a possible treatment for tardive dyskinesia?
"
11/01/1980 - "
Since many studies have linked the development of neuroleptic induced tardive dyskinesias with enhanced sensitivity of brain dopamine receptors, and the latter was blocker by cyclo (Leu-Gly), this agent may be of value in preventing the development of symptoms of neuroleptic-induced tardive dyskinesias.
"
04/01/1984 - "
These studies suggest that the hypothalamic peptide, Pro-Leu-Gly-NH2 and its long-acting analog, cyclo (Leu-Gly) can prevent the development of both behavioral and biochemical supersensitivity of dopamine receptors in brain induced by neuroleptic drugs and that these peptides may be useful in preventing the development of neuroleptic-induced tardive dyskinesia.
"
3.
Hypertension (High Blood Pressure)
05/02/1983 - "
These studies suggest that cyclo(Leu-Gly) interacts with the dopamine receptors and that the central dopamine receptors may play a role in the pathophysiology of hypertension.
"
4.
Catalepsy
08/01/1981 - "
Multiple injections of MIF or cyclo(Leu-Gly) did not alter beta-endorphin-induced analgesia, catalepsy and hypothermia in rats which were given repeated intraventricular injections of saline.
"
02/01/1982 - "
The effects of melanotropin release inhibiting factor (Pro-Leu-Gly-NH2; MIF) and its three analogs Pro-ILeu-Gly-NHi2, Leu-Gly-NH2 (a metabolite of MIF) and cyclo (Leu-Gly) (an analog derived theoretically from MIF) on tolerance to morphine-induced hyperthermia, hypothermia and catalepsy were studied in male Sprague-Dawley rats.
"
09/01/1991 - "
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
"
5.
Hypothermia
08/01/1981 - "
Multiple injections of MIF or cyclo(Leu-Gly) did not alter beta-endorphin-induced analgesia, catalepsy and hypothermia in rats which were given repeated intraventricular injections of saline.
"
02/01/1982 - "
The effects of melanotropin release inhibiting factor (Pro-Leu-Gly-NH2; MIF) and its three analogs Pro-ILeu-Gly-NHi2, Leu-Gly-NH2 (a metabolite of MIF) and cyclo (Leu-Gly) (an analog derived theoretically from MIF) on tolerance to morphine-induced hyperthermia, hypothermia and catalepsy were studied in male Sprague-Dawley rats.
"
Related Drugs and Biologics
1.
Peptides (Polypeptides)
2.
Puromycin
3.
Lypressin
4.
Arginine Vasopressin (Argipressin)
5.
carbobenzoxyprolyl-leucyl-glycinamide
6.
Dopamine Receptors (Dopamine Receptor)
7.
Antipsychotic Agents (Antipsychotics)
8.
MSH Release-Inhibiting Hormone (MIF-I)
9.
Morphine (MS Contin)
10.
Phosphoric Diester Hydrolases (Phosphodiesterases)
Related Therapies and Procedures
1.
Intraventricular Injections
2.
Injections
3.
Induced Hyperthermia (Thermotherapy)
4.
Analgesia